Preveceutical Medical Inc. (18H.SG)
| Previous Close | 0.0172 |
| Open | 0.0160 |
| Bid | 0.0220 x 0 |
| Ask | 0.0268 x 0 |
| Day's Range | 0.0160 - 0.0160 |
| 52 Week Range | 0.0084 - 0.0300 |
| Volume | |
| Avg. Volume | 422 |
| Market Cap | N/A |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Newsfile
PreveCeutical Enters into Credit Facility Agreement
Vancouver, British Columbia--(Newsfile Corp. - July 22, 2022) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), announces that it has entered into a $3 million credit facility agreement with the Company's Chief Executive Officer and Chair, Stephen Van Deventer, and the Company's former President and director, Kimberly Van Deventer (collectively, the "Lenders").Effective July 18, 2022, the Company entered into a convertible credit facility agre
- Newsfile
PreveCeutical Announces Change in Directors and Investor Awareness Services
Vancouver, British Columbia--(Newsfile Corp. - May 27, 2022) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), announces the resignation of Mr. Anderson and Mr. Lotz and the appointment of Dr. Linnéa Olofsson to the Company's board of directors (the "Board").Resignation of DirectorsMr. Keith Anderson and Mr. Mark Lotz will be stepping down as directors of the Company effective May 31, 2022, to allow them more time to focus ...
- Newsfile
Article Based on PreveCeutical's Pain Management Peptides Program Published in the British Journal of Pharmacology
Vancouver, British Columbia--(Newsfile Corp. - May 9, 2022) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce that the British Journal of Pharmacology (the "BJP"), published an article on April 29, 2022, on the design and development of its non-addictive analgesic program ("Analgesic Program") under the running title, "Short dynorphin-like peptide agonists for kappa opioid receptors" click here to see the report. The art
